Creek Drive Management Group LLC Acquires 41,500 Shares of Hims & Hers Health, Inc. $HIMS

Creek Drive Management Group LLC boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 70.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 100,000 shares of the company’s stock after purchasing an additional 41,500 shares during the period. Creek Drive Management Group LLC’s holdings in Hims & Hers Health were worth $2,979,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Bank of America Corp DE raised its position in shares of Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $46,220,000. Bienville Capital Management LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at approximately $27,242,000. Southpoint Capital Advisors LP acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at approximately $10,380,000. Finally, Swiss National Bank grew its position in shares of Hims & Hers Health by 1.1% in the 1st quarter. Swiss National Bank now owns 390,500 shares of the company’s stock valued at $8,107,000 after purchasing an additional 4,300 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 3,518 shares of the stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $18.53, for a total transaction of $65,188.54. Following the completion of the transaction, the chief financial officer directly owned 266,188 shares in the company, valued at $4,932,463.64. This represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the completion of the transaction, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. The trade was a 2.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,041 shares of company stock valued at $2,764,840 over the last quarter. 11.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on HIMS. Morgan Stanley lowered their target price on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 10th. Citigroup cut their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They set a “neutral” rating and a $32.00 price objective for the company. Finally, Needham & Company LLC lowered their price objective on shares of Hims & Hers Health from $42.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, November 10th. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $31.53.

Read Our Latest Research Report on HIMS

Hims & Hers Health Price Performance

NYSE HIMS opened at $17.12 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.92 and a debt-to-equity ratio of 3.85. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $40.99. The company has a market capitalization of $4.01 billion, a PE ratio of -20.63 and a beta of 2.53. The firm’s 50 day moving average is $27.00 and its 200-day moving average is $26.54.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The business had revenue of $890.37 million during the quarter, compared to the consensus estimate of $893.13 million. During the same period in the prior year, the firm earned $0.06 EPS. The business’s revenue for the quarter was up 48.6% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.21 earnings per share for the current fiscal year.

Key Stories Impacting Hims & Hers Health

These are some of the HIMS stories that stood out recently:

  • Positive Sentiment: Hims & Hers launched Peptides+, a provider-guided specialty service offering five treatments, expanding its services into cellular and proactive health. The company is also adding FDA-approved obesity drugs to its platform, potentially widening its weight-loss offering. Hims & Hers launches Peptides+ FDA-approved obesity drugs added to the platform
  • Negative Sentiment: Recent results missed analyst expectations: quarterly EPS was $0.03 versus $0.06 expected, and revenue also came in slightly below estimates. Coverage also highlighted the loss of 100,000 subscribers, raising questions about customer retention even as the company expands its offerings. Coverage of Hims & Hers’ results and stock decline Subscriber-loss coverage
  • Negative Sentiment: Two insiders, including CFO Oluyemi Okupe, sold shares. Both trades were made under pre-arranged Rule 10b5-1 plans, and the CFO retained a substantial stake, which may temper—but does not eliminate—the negative signal investors can read from insider sales. CFO sale SEC filing Deborah Autor sale SEC filing

Hims & Hers Health Company Profile

(Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Featured Articles

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Free Report).

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.